The current guidelines for GC recommend nivolumab combined with chemotherapy as first-line regimen and nivolumab monotherapy as third-line regimen for advanced or metastatic GC with HER2-negative, including liver metastasis (12, 13). The gene discussed is ERBB2; the disease is gastric cancer.